Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wockhardt Limited (WOCKPHARMA.NS)
Mumbai, MH, IN
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.82% | +5.08% | +20.99% | +24.68% | +32.95% | +17.56% | +27.39% | +887.34% | +134.54% | +104.92% | +583.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+11.1% ★ Q1'26: +26.0% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+533.8% ★ Q1'26: +742.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-1.2% Q1'26: +12.3% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+12.0% ★ Q1'26: +14.8% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+4.9% Q1'26: +7.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+3.6% Q1'26: +2.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×3.54× Q1'26: 2.85× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
46.14B
est: 43.72B (+5.5%)
|
56.26B
est: 56.98B (-1.3%)
|
48.30B
est: 48.79B (-1.0%)
|
44.82B
est: 44.97B (-0.3%)
|
44.53B
est: 46.51B (-4.3%)
|
39.66B
est: 43.68B (-9.2%)
|
39.24B
est: 42.46B (-7.6%)
|
35.66B
est: 41.89B (-14.9%)
|
| EBITDA |
9.14B
est: 1.75B (+421.5%)
|
21.07B
est: 10.52B (+100.2%)
|
9.80B
est: 20.69B (-52.7%)
|
8.27B
est: 9.23B (-10.4%)
|
5.03B
est: 5.97B (-15.9%)
|
206.60M
est: 1.72B (-88.0%)
|
-610.70M
est: -1.96B (+68.9%)
|
-181.10M
est: 1.69B (-110.7%)
|
| EBIT |
7.88B
est: -803.90M (+1,080.7%)
|
19.85B
est: 10.29B (+93.0%)
|
8.40B
est: 17.38B (-51.7%)
|
6.82B
est: 8.20B (-16.9%)
|
3.68B
est: 7.05B (-47.9%)
|
-1.23B
est: -787.28M (-55.9%)
|
-2.05B
est: -1.21B (-69.3%)
|
-1.77B
est: -774.12M (-128.7%)
|
| Net Income |
3.43B
est: 12.03B (-71.5%)
|
15.79B
est: 4.47B (+253.5%)
|
8.41B
est: 13.65B (-38.4%)
|
4.05B
est: 7.75B (-47.8%)
|
2.51B
est: 4.19B (-40.1%)
|
-1.96B
est: 4.09B (-147.9%)
|
-6.08B
est: -1.93B (-215.0%)
|
-1.95B
est: 3.27B (-159.5%)
|
| SGA |
4.80B
est: 10.52B (-54.4%)
|
11.82B
est: 15.01B (-21.3%)
|
13.90B
est: 10.72B (+29.6%)
|
9.44B
est: 13.13B (-28.1%)
|
10.39B
est: 16.16B (-35.7%)
|
10.54B
est: 10.30B (+2.3%)
|
10.29B
est: 17.68B (-41.8%)
|
8.94B
est: 10.13B (-11.7%)
|
| EPS |
28.85
est: 76.65 (-62.4%)
|
144.22
est: 141.02 (+2.3%)
|
76.64
est: 68.01 (+12.7%)
|
36.81
est: 35.72 (+3.1%)
|
22.71
est: 41.88 (-45.8%)
|
-17.71
est: 26.18 (-167.7%)
|
-55.01
est: 23.06 (-338.5%)
|
-26.17
est: 20.73 (-226.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.04% | 6.07M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 203.1K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 458.2K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.01% | 22.61M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.01% | 378.7K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 24.53M | 0.05% |
| 7 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 50.6K | 0.24% |
| 8 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 50.6K | 0.24% |
| 9 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 36.3K | 0.22% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 1.33M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Habil Fakhruddin Khorakiwala | Founder & Executive Chairman | 37M | — |
| Huzaifa Habil Khorakiwala | Executive Director | 25M | — |
| Murtaza Habil Khorakiwala | MD & Executive Director | 25M | — |
| Rashmi Dinesh Mamtura | Company Secretary & Compliance Officer | — | female |
| Sachin Bhagwat | Chief Scientific Officer | — | — |
| Satej Mehta | Head of Human Resource | — | male |
| Anil V. Kamath AMRSH MBIM MIMA | Senior Vice President of Business Development | — | male |
| Zoher T. Sihorwala | Head of Global Regulatory Affairs | — | male |
| Debolina Partap | Senior Vice President of Legal | — | female |
| Deepak Madnani | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WOCKPHARMA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
